Globus Medical Inc. (GMED)
GMED trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1237831/000162828026011209/0001628280-26-011209-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GMED on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2012 |
| SEC CIK | 0001237831 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.9B |
| Net income | $537.9M |
| Operating income | $479.8M |
| Net margin | 18.3% |
| Operating margin | 16.3% |
| Revenue growth | +16.7% |
| Cash | $526.2M |
| Total assets | $5.3B |
| P/E (computed) | 17.4× |
| P/S (computed) | 3.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $441.3M cash; operating cash flow $231.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 132,471,693 (2026-11-02). | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $17.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $763.7M | $141.2M | $265.2M | $441.3M | No debt tags | $3.1B | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $789.6M | $151.6M | $209.7M | $507.7M | No debt tags | $3.1B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $759.9M | $124.3M | $202.4M | $561.0M | No debt tags | $3.1B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $826.4M | $140.6M | $248.6M | $526.2M | No debt tags | $2.9B | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $769.0M | $119.0M | $249.7M | $371.8M | No debt tags | $2.8B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $745.3M | $202.8M | $77.9M | $229.4M | No debt tags | $2.6B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $598.1M | $75.5M | $177.3M | $461.3M | No debt tags | $2.5B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $657.3M | $26.5M | $210.3M | $784.4M | No debt tags | $2.5B | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2023-03-28 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 780 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.5% |
| 1 month | -5.5% |
| 3 months | -16.1% |
| Year to date | -17.4% |
| 1 year | -14.1% |
| From 52-week high | -25.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PODD | Insulet Corporation | $145.29 | -4.72% | $10.1B |
| PEN | Penumbra Inc. | $320.62 | -0.09% | $12.6B |
| BAX | Baxter International Inc. | $25.54 | -1.05% | $13.2B |
| TFX | Teleflex Incorporated | $157.10 | +1.51% | $6.2B |
| GKOS | Glaukos Corporation | $244.88 | -0.34% | $14.5B |
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
| HAE | Haemonetics Corporation | $121.34 | -1.30% | $5.5B |
| MMED | MiniMed Group Inc. | $18.65 | +3.67% | $5.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier